Prevalence and Associated Factors of Anemia among Breast Cancer Patients Undergoing Chemotherapy: A Prospective Study

Table 1

Demographic and clinical data for the 292 patients included in the study.

Variable		N (%)
Hospital name	HKL	93 (31.8%)
	UMMC	80 (27.4%)
	NCI	119 (40.1%)
Mean age/years	52.77 (SD 10.25)
Age/years	≥60	159 (54.5%)
	<60	133 (45.5%)
Race	Malay	169 (57.9%)
	Indian	39 (13.4%)
	Chinese	70 (24%)
	Others	14 (4.8%)
Marital status	Married	261 (89.4%)
	Single	17 (5.8%)
	Divorced	14 (4.8%)
Body mass index (BMI) kg/m^2	Obese BM (≥25)	118 (40.4%)
	Nonobese BMI (<25)	174 (59.6%)
Employment status	Employed	195 (66.8%)
	Nonemployed	97 (33.2%)
Social status	Smoking	20 (6.8%)
	Nonsmoking	272 (93.2%)
Menopausal status	Pre	92 (31.5%)
	Post	200 (68.5%)
Stage of breast cancer	Stage I	22 (7.5%)
	Stage II	81 (27.7%)
	Stage III	124 (42.5%)
	Stage IV	65 (22.3%)
Number of regimen	1	141 (48.3%)
	> 1	151 (51.7%)
Dose delay	Delayed	128 (43.8%)
	Not delayed	164 (56.2%)
Dose reduction	Reduced	51 (17.5%)
	Not reduced	204 (69.9%)
	Not detected	37 (12.7%)
FEC	Received	131 (44.9%)
Docetaxel	Received	79 (27.1%)

Fluorouracil, Epirubicin, Cyclophosphamide.